HaemaLogiX Overview
- Status
- Private
- Employees
- 4
- Latest Deal Type
- Accelerator/Inc
- Investors
- 1
HaemaLogiX General Information
Description
Developer of novel immuno-oncology and immune-therapies intended for the treatment of haematologic malignancies and auto-immune diseases. The company's mmuno-oncology and immune-therapies enables blood cancers patient to have extended survival time from the disease.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Suite 145
- 4 Cornwallis Street
- Eveleigh, New South Wales 2015
- Australia
+61 (02) 0000 0000
HaemaLogiX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | Completed | Startup |
HaemaLogiX Executive Team (3)
HaemaLogiX Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alan Liddle | HaemaLogiX | Board Member | 000 0000 |
| Bryce Carmine | HaemaLogiX | Chief Executive Officer & Chairman | 000 0000 |
| John Cullity | HaemaLogiX | Board Member | 000 0000 |
HaemaLogiX Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialHaemaLogiX Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Cicada Innovations | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |